|
MaxCyte Inc - Gaithersburg, Maryland-based platform for cell-based research - Signs a strategic platform license agreement with Korean chemical company LG Chem Ltd, a subsidiary of LG Corp. Explains that the deal gives LG non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. MaxCyte will receive platform licensing fees and programme related revenue.
‘This partnership represents our first strategic platform license with a South Korean company and broadens our reach into Asia to provide advanced technologies that support the clinical and commercial development of engineered cell therapies, and ultimately change the lives of patients with cancer,’ Chief Executive & President Doug Doerfler says.
Current stock price: 424.00 pence, up 2.2% on Tuesday in London
12-month change: down 61%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
